[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Michel Doepke [@doepke_michel](/creator/twitter/doepke_michel) on x 4855 followers Created: 2025-07-01 13:22:46 UTC $PTGX Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity. $NVO $LLY $VKTX XXXXX engagements  **Related Topics** [$lly](/topic/$lly) [$ptgx](/topic/$ptgx) [$nvo](/topic/$nvo) [stocks healthcare](/topic/stocks-healthcare) [eli lilly](/topic/eli-lilly) [$vktx](/topic/$vktx) [Post Link](https://x.com/doepke_michel/status/1940038371616657641)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Michel Doepke @doepke_michel on x 4855 followers
Created: 2025-07-01 13:22:46 UTC
$PTGX Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity. $NVO $LLY $VKTX
XXXXX engagements
Related Topics $lly $ptgx $nvo stocks healthcare eli lilly $vktx
/post/tweet::1940038371616657641